Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $340000.0.

  • Vivos Therapeutics' Change in Account Payables rose 13567.68% to $340000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $970000.0, marking a year-over-year increase of 31365.64%. This contributed to the annual value of -$1.0 million for FY2024, which is 24277.93% down from last year.
  • According to the latest figures from Q3 2025, Vivos Therapeutics' Change in Account Payables is $340000.0, which was up 13567.68% from $499000.0 recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Change in Account Payables ranged from a high of $902000.0 in Q3 2021 and a low of -$1.4 million during Q1 2021
  • Over the past 5 years, Vivos Therapeutics' median Change in Account Payables value was $204000.0 (recorded in 2023), while the average stood at $66526.3.
  • Within the past 5 years, the most significant YoY rise in Vivos Therapeutics' Change in Account Payables was 32142.86% (2024), while the steepest drop was 56715.69% (2024).
  • Quarter analysis of 5 years shows Vivos Therapeutics' Change in Account Payables stood at $220000.0 in 2021, then surged by 248.64% to $767000.0 in 2022, then decreased by 19.69% to $616000.0 in 2023, then tumbled by 96.43% to $22000.0 in 2024, then soared by 1445.45% to $340000.0 in 2025.
  • Its Change in Account Payables was $340000.0 in Q3 2025, compared to $499000.0 in Q2 2025 and $109000.0 in Q1 2025.